Company Presentation • 21 Aug 2026 19:15
H1 2026
Company Presentation • 20 Aug 2024 15:30
H1 2020
Company Presentation • 24 Aug 2020 15:30
H1 2020
Company Presentation • 26 Mar 2021 15:30
H2 2020
Company Presentation • 25 Aug 2025 16:00
𝛼SK or SearchENTITY
Shanghai Henlius Biotech (2696 HK)
Shanghai Henlius Biotech (2696 HK)
367
Analysis
Health Care • China
Shanghai Henlius Biotech is a global, innovation-driven biopharmaceutical company focused on delivering high-quality, affordable biologic therapies for oncology, autoimmune diseases, and ophthalmic diseases. The company is engaged in biopharmaceutical research and development, manufacturing, and commercialization, offering products such as the biosimilars HANLIKANG (rituximab), HANQUYOU (trastuzumab), HANDAYUAN (adalimumab), and HANBEITAI (bevacizumab), as well as the innovative biologic HANSIZHUANG (serplulimab). Headquartered in Shanghai, China, the company was founded in 2010.
morex